功能性消化不良治疗STW 5-II的有效性和安全性:基于患者数据的元分析
Viola Andresen1, Ayesha Shah2,3, Careen Fink4
1Medizinicum, Hamburg, Germany.
Digestion
|January 21, 2024
概括
这次元分析发现,STW 5-II在4周和8周后显著改善了功能性消化不良 (FD) 的症状. 草药治疗表明了有利的安全性,与安慰剂相比,使其成为FD管理的可行选择.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 草药是一种草药.
背景情况:
- 功能性消化不良 (FD) 是一种普遍存在的胃肠道疾病,治疗选择有限.
- 草药,如六种草药组合STW 5-II,提供一种潜在的多症状方法来管理FD.
- 本研究评估了STW 5-II对FD的有效性和安全性,基于罗马IV标准.
研究的目的:
- 进行一项元分析,评估STW 5-II在治疗整体功能性消化不良症状方面的疗效.
- 评估STW 5-II对主要FD症状的影响,包括腹感,早期腹感和上胃疼痛.
- 在FD患者中,确定STW 5-II与安慰剂相比的安全性概况.
主要方法:
- 对随机对照试验 (RCT) 进行系统的文献搜索,调查FD的STW 5-II.
- 从符合条件的RCT中对个体患者数据的元分析,重点是患有中度至重度FD症状的患者.
- 基于ANCOVA的4周和8周症状改善的分析,以及不良事件的安全性评估.
主要成果:
- 两项与613名患者的RCT被纳入了疗效分析.
- STW 5-II在4周和8周的总FD症状得分中显示出统计学上显著的改善.
- 关键的FD症状,包括腹感,早期和腹上疼痛,被STW 5-II显著缓解,与安慰剂相比,不良事件没有显著差异.
结论:
- STW 5-II是功能性消化不良的有效治疗方法,显著改善核心症状.
- 草药组合STW 5-II表现出与安慰剂可比的安全性.
- STW 5-II为治疗功能性消化不良提供了一种安全有效的治疗选择.
相关概念视频
01:26Peptic Ulcer Disease IV: Management
94
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
94
01:17Drugs for Treatment of Diarrhea-Predominant IBS
176
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
176
01:21Drugs for Treatment of Constipation-Predominant IBS
170
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
170
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
261
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
261
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
88
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
88
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
163
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
163